Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

NCT00138619 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

478

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: vildagliptin

Sponsor

Novartis